A review and update on cholangiocarcinoma

Oncology

Volumn 66, Issue 3, 2004, Pages 167-179

  Olnes, Matthew J ^a   Erlich, Rodrigo ^b  

^a JOHNS HOPKINS BAYVIEW MEDICAL CENTER   (United States)

^b SINAI HOSPITAL OF BALTIMORE   (United States)

Author keywords

Bile duct cancer; Chemotherapy; Cholangiocarcinoma; Hilar; Intrahepatic; Perihilar; Primary sclerosing cholangitis

Indexed keywords

ALPHA2B INTERFERON; ANTINEOPLASTIC AGENT; CAPECITABINE; CARBOPLATIN; CYCLOOXYGENASE 2; DOXIFLURIDINE; DOXORUBICIN; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; IRIDIUM; K RAS PROTEIN; LOMUSTINE; MITOGEN ACTIVATED PROTEIN KINASE; MITOMYCIN C; PROTEIN P53; STREPTOZOCIN; THYROID HORMONE RECEPTOR BETA;

BEAM THERAPY; BILE DUCT CARCINOMA; BRACHYTHERAPY; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CLINICAL FEATURE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; DISEASE CLASSIFICATION; GENE EXPRESSION; GENE MUTATION; GENE OVEREXPRESSION; GRAFT REJECTION; HUMAN; LIVER TRANSPLANTATION; PATHOGENESIS; PRIORITY JOURNAL; REVIEW;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BILE DUCT NEOPLASMS; BILE DUCTS, INTRAHEPATIC; CHOLANGIOCARCINOMA; CHOLANGITIS, SCLEROSING; DIAGNOSIS, DIFFERENTIAL; HUMANS; NEOPLASM STAGING; TUMOR MARKERS, BIOLOGICAL;

EID: 3042663173     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000077991     Document Type: Review

References (128)

1. Renshaw K: Malignant neoplasms of the extrahepatic biliary ducts. Ann Surg 1922;76:205-221.
2. Stewart HL, Lieber MM, Morgan DR: Carcinoma of the extrahepatic bile ducts. Arch Surg 1940;41:662-713.
3. American Cancer Society Cancer Facts and Figures: Available at: www.cancer.org 2003.
4. Patel T: Increasing incidence and mortality of primary intrahepatic cholangiocarcinoma in the United States. Hepatology 2001;33:1353-1357.
5. Taylor-Robinson SD, Toledano MB, Arora S, Keegan TJ, Hargreaves S, Beck A, Khan SA, Elliott P, Thomas HC: Increase in mortality rates from intrahepatic cholangiocarcinoma in England and Wales 1968-1998. Gut 2001;48:816-820.
6. Khan SA, Taylor-Robinson SD, Toledano MB, Beck A, Elliott P, Thomas HC: Changing international trends in mortality rates for liver, biliary, pancreatic tumours. J Hepatol 2002;37:806-813.
7. Mouzas IA, Dimoulios P, Vlachonikolis IG, Skordilis P, Zoras O, Kouroumalis E: Increasing incidence of cholangiocarcinoma in Crete 1992-2000. Anticancer Res 2002;22:3637-3641.
8. Green A, Uttaravichien T, Bhudhisawasdi V, Chartbanchachai W, Elkins DB, Marleng EO, et al: Cholangiocarcinoma in northeast Thailand. A hospital-based study. Trop Geogr Med 1991;43:193-198.
9. Rosen CB, Nagorney DM, Wiesner RH, Coffey RJJ, LaRusso NF: Cholangiocarcinoma complicating primary sclerosing cholangitis. Ann Surg 1991;213:21-25.
10. Broome U, Olsson R, Loof L, Bodemar G, Hultcrantz R, Danielsson A, Prytz H, Sandberg-Gertzen H, Wallerstedt S, Lindberg G: Natural history and prognostic factors in 305 Swedish patients with primary sclerosing cholangitis. Gut 1996;38:610-615.
11. Farrant JM, Hayllar KM, Wilkinson ML, Karani J, Portmann BC, Westaby D, Williams R: Natural history and prognostic variables in primary sclerosing cholangitis. Gastroenterology 1991;100:1710-1707.
12. Harrison PM: Prevention of bile duct cancer in primary sclerosing cholangitis. Ann Oncol 1999;10:S208-S211.
13. Fleming KA, Boberg KM, Glaumann H, Bergquist A, Smith D, Clausen OP: Biliary dysplasia as a marker of cholangiocarcinoma in primary sclerosing cholangitis. J Hepatol 2001;34:360-365.
14. Kaya M, de Groen P, Angulo P, Nagorney DM, Gunderson LL, Gores GJ, Haddock MG, Lindor KD: Treatment of cholangiocarcinoma complicating primary sclerosing cholangitis: The Mayo Clinic experience. Am J Gastroenterol 2001;96:1164-1169.
15. Gores GJ: Early detection and treatment of cholangiocarcinoma. Liver Transplant 2000;6:S30-S34.
16. Johnson KJ, Olliff JF, Oliff SP: The presence and significance of lymphadenopathy detected by CT in primary sclerosing cholangitis. Br J Radiol 1998;71:1279-1282.
17. Bergquist A, Tribukait B, Glaumann H, Broome U: Can DNA cytometry be used for evaluation of malignancy and premalignancy in bile duct strictures in primary sclerosing cholangitis? J Hepatol 2000;33:873-877.
18. Lipsett PA, Pitt HA, Colombani PM, et al: Choledochal cyst disease. A changing pattern of presentation. Ann Surg 1994;220:644-652.
19. Chapman RW: Risk factors for biliary tract carcinogenesis. Ann Oncol 1999;10:308-311.
20. Kubo S, Kinoshita H, Hirohashi K, Hamba H: Hepatolithiasis associated with cholangiocarcinoma. World J Surg 1995;639-641.
21. Lesurtel M, Regimbeau JM, Farges O, Colombat M, Sauvanet A, Belghiti J: Intrahepatic cholangiocarcinoma and hepatolithiasis: An unusual association in Western countries. Eur J Gastroenterol Hepatol 2002;14:1025-1027.
22. Su CH, Shyr YM, Lui WY, P'Eng FK: Hepatolithiasis associated with cholangiocarcinoma. Br J Surg 1997;84:959-973.
23. Strong RW, Chew SP, Wall DR, Fawcett J, Lynch SV. Liver transplantation for hepatolithiasis. Asian J Surg 2002;25:180-182.
24. Kim YT, Byun JS, Kim J, Jang YH, Lee WJ, Ryu JK, Kim SW, Yoon YB, Kim CY: Factors predicting concurrent cholangiocarcinomas associated with hepatolithiasis. Hepatogastroenterology 2003;50:8-12.
25. Watanapa P, Watanapa WB. Liver fluke-associated cholangiocarcinoma. Br J Surg 2002;89:962-970.
26. Kurathong S, Lerdverasirikul P, Wongpaitoon V, Kanjanapitak A, Varavithya W, Phuapradit P, Bunyaratvej S, Upatham ES, Brockelman WY: Opisthorchis viverrini infection and cholangiocarcinoma. A prospective, case-controlled study. Gastroenterology 1985;89:151-156.
27. Tesana S, Takahashi Y, Sithithaworn P, Ando K, Tenruyo S, Yutanawiboonchai W, Pairojkul C, Ruangjirachuporn W: Ultrastructural and immunohistochemical analysis of cholangiocarcinoma in immunized Syrian golden hamsters infected with O. viverrini and administered dimethylnitrosamine. Parasitol Int 2000;49:239-251.
28. Kim KH, Kim CD, Lee HS, Lee SJ, Jeen YT, Chun JH, Song CW, Lee SW, Um SH, Choi JH, Ryu HS, Hyun JH: Biliary papillary hyperplasia with clonorchiasis resembling cholangiocarcinoma. Am J Gastroenterol 1999;94:514-517.
29. Rubel LR, Ishak KG: Thorotrast-associated cholangiocarcinoma: An epidemiologic and clinicopathologic study. Cancer 1982;50:1408-1415.
30. Van Kaick G, Dalheimer A, Hornik S, Kaul A, Liebermann D, Luhrs H, Spiethoff A, Wegener K, Wesch H: The German thorotrast study: Recent results and assessment of risks. Radiat Res 1999;152:S64-S71.
31. Sharp GB: The relationship between internally deposited alpha-particle radiation and subsitespecific liver cancer and liver cirrhosis: An analysis of published data. J Radiat Res 2002;43:371-380.
32. Gilbert ES, Koshurnikova NA, Sokolnikov M, Khokhryakov VF, Miller S, Preston DL, Romanov SA, Shilnikova NS, Suslova KG, Vostrotin VV: Liver cancers in Mayak workers. Radiat Res 2000;154:246-252.
33. Sturm PD, Baas IO, Clement MJ, Nakeeb A, Offerhaus GJ, Hruban RH, Pitt HA: Alterations of the p53 tumor suppressor gene and Kras oncogene in perihilar cholangiocarcinomas from a high incidence area. Int J Cancer 1998;78:695-698.
34. Szendroi M, Nemeth L, Vajta G: Asbestos bodies in a bile duct cancer after occupational exposure. Environ Res 1983;30:270-277.
35. Brown DP: Mortality of workers exposed to polychlorinated biphenyls - An update. Arch Environ Health 1987;42:333-339.
36. Mitacek EJ, Brunnemann KD, Hoffmann D, Limsila T, Suttajit M, Martin N, Caplan LS: Volatile nitrosamines and tobacco-specific nitrosamines in the smoke of Thai cigarettes: A risk factor for lung cancer and a suspected risk factor for liver cancer in Thailand. Carcinogenesis 1999;20:133-137.
37. Bergquist A, Glaumann H, Persson B, Broome U: Risk factors and clinical presentation of hepatobiliary carcinoma in patients with primary sclerosing cholangitis: A case control study. Hepatology 1998;27:311-316.
38. Lowenfelds AB, Norman J: Isoniazid and bile duct cancer. JAMA 1978;240:434-435.
39. Yen S, Hsieh CC, Macmahon B: Extrahepatic bile duct cancer and smoking, beverage consumption, past medical history, and oral-contraceptive use. Cancer 1987:59:2112-2116.
40. Bertazzi PA, Consonni D, Bachetti S, Rubagotti M, Baccarelli A, Zocchetti C, Pesatori AC: Health effects of dioxin exposure: A 20-year mortality study. Am J Epidemiol 2001;153:1031-1044.
41. Ohashi K, Nakajima Y, Kanehiro H, Tsutsumi M, Taki J, Aomatsu Y, Yoshimura A, Ko S, Kin T, Yagura K, et al: Ki-ras mutations and p53 protein expressions in intrahepatic cholangiocarcinomas: Relation to gross tumor morphology. Gastroenterology 1995;109:1612-1617.
42. Isa T, Tomita S, Nakachi A, Miyazato H, Shimoji H, Kusano T, Muto Y, Furukawa M: Analysis of microsatellite instability, K-ras mutation and p53 protein overexpression in intrahepatic cholangiocarcinoma. Hepatogastroenterology 2002;49:604-608.
43. Rashid A, Ueki T, Gao Y-T, Houlihan PS, Wallace C, Wang B-S, Shen M-C, Deng J, Hsing AW: K-ras mutation, p53 overexpression, and microsatellite instability in biliary tract cancers: A population-based study in China. Clin Cancer Res 2002;8:3156-3163.
44. Diamantis I, Karamitopoulou E, Perentes E, Zimmermann A: p53 protein immunoreactivity in extrahepatic bile duct and gallbladder cancer: Correlation with tumor grade and survival. Hepatology 1995;22:774-779.
45. Kang YK, Kim WH, Lee HW, Lee HK, Kim YI: Mutations of p53 and K-ras, and loss of heterozygosity of APC in intrahepatic cholangiocarcinoma. Lab Invest 1999;79:477-483.
46. Kamikawa T, Amenomori M, Itoh T, Momoi H, Hiai H, Machinami R, Ishikawa Y, Mori Y, Shimahara Y, Yamoaka Y, Fukumoto M: Analysis of genetic changes in intrahepatic cholangiocarcinoma induced by thorotrast. Radiat Res 1999;152:S118-124.
47. Liu D, Momoi H, Li L, Ishikawa Y, Fukumoto M: Microsatellite instability in thorotrast-induced human intrahepatic cholangiocarcinoma. Int J Cancer 2002;102:366-371.
48. Limpaiboon T, Krissadarak K, Sripa B, Jearanaikoon P, Vajarabhongsa B, Chau-in S, Amornrat R, Pairojkul C: Microsatellite alterations in liver fluke related cholangiocarcinoma are associated with a poor prognosis. Cancer Lett 2002;181:215-222.
49. Lee S, Kim WH, Jung H-Y, Yang MH, Kang GH: Aberrant CpG island methylation of multiple genes in intrahepatic cholangiocarcinoma. Am J Pathol 2002;161:1015-1022.
50. Tannapfel A, Sommerer F, Benicke M, Weinans L, Katalinic A, Geissler F, Uhlmann D, Hauss J, Wittekind C: Genetic and epigenetic alterations of the INK4a-ARF pathway in cholangiocarcinoma. J Pathol 2002;197:624-631.
51. Taniai M, Higuchi H, Burgart LJ, Gores GJ: P16INK4a promoter mutations are frequent in primary sclerosing cholangitis (PSC) and PSC-associated cholangiocarcinoma. Gastroenterology 2002;123:1090-1098.
52. Wong N, Li L, Tsang K, Lai PB, To KF, Johnson PJ: Frequent loss of chromosome 3p and hypermethylation of RASSF1A in cholangiocarcinoma. J Hepatol 2002;37:633-639.
53. Sugimachi K, Taguchi K-I, Aishima S-I, Tanaka S, Shimada M, Kajiyama K, Sugimachi K, Tsuneyoshi M: Altered expression of beta-catenin without genetic mutation in intrahepatic cholangiocarcinoma. Mod Pathol 2001;14:900-905.
54. Benckert C, Jonas S, Cramer T, Marschall ZV, Schafer G, Peters M, Wagner K, Radke C, Wiedenmann B, Neuhaus P, Hocker M, Rosewicz S: Transforming growth factor β1 stimulates vascular endothelial growth factor gene transcription in human cholangiocellular carcinoma cells. Cancer Res 2003;63:1083-1092.
55. Kang KK, Kim WH, Jang JJ: Expression of G1-S modulators (p53, p16, p27, cyclin D1, Rb) and Smad4/Dpc4 in intrahepatic cholangiocarcinoma. Human Pathol 2002;877-883.
56. Date K, Matsumoto K, Kuba K, Shimura H, Tanaka M, Nakamura T: Inhibition of tumor growth and invasion by a four-kringle antagonist (HGF/NK4) for hepatocyte growth factor. Oncogene 1998;17:3045-3054.
57. Sirica AE, Lai G-H, Zhang Z: Biliary cancer growth factor pathways, cyclo-oxygenase-2 and potential therapeutic strategies. J Gastroenterol Hepatol 2001;16:363-372.
58. Aishima SI, Taguchi KI, Sugimachi K, Shimada M, Sugimachi K, Tsuneyoshi M: c-erbB-2 and c-Met expression relates to cholangiocarcinogenesis and progression of intrahepatic cholangiocarcinoma. Histopathology 2002;40:269-278.
59. Chariyalertsak S, Sirikulchayanonta V, Mayer D, Kopp-Schneider A, Fürstenberger G, Marks F, Müller-Decker K: Aberrant cyclooxygenase isozyme expression in human intrahepatic cholangiocarcinoma. Gut 2000;48:80-86.
60. Ito Y, Miyoshi E, Takeda T, Sakon M, Tsujimoto M, Yokosaki Y, Monden M, Matsuura N: Ets-1 expression in extrahepatic bile duct carcinoma and cholangiocellular carcinoma. Oncology 2000;58:248-252.
61. Ukita Y, Kato M, Terada T: Gene amplification and mRNA and protein overexpression of c-erbB-2 (HER-2/neu) in human intrahepatic cholangiocarcinoma as detected by fluorescence in situ hybridization, in situ hybridization, immunohistochemistry. J Hepatol 2002;36:780-785.
62. Endo K, Yoon B-I, Pairojkul C, Demetris AJ, Sirica AE: ERBB-2 overexpression and cyclooxygenase-2 up-regulation in human cholangiocarcinoma and risk conditions. Hepatology 2002;439-450.
63. Wu GS, Zou SQ, Luo XW, Wu JH, Liu ZR: Proliferative activity of bile from congenital choledochal cyst patients. World J Gastroenterol 2003;9:184-187.
64. Yoon JH, Higuchi H, Werneburg NW, Kaufmann SH, Gores GJ: Bile acids induce cyclooxygenase-2 expression via the epidermal growth factor receptor in a human cholangiocarcinoma cell line. Gastroenterology 2002;122:985-993.
65. Sirica AE, Li GH, Endo K, Zhang Z, Yoon BI: Cyclooxygenase-2 and erb-2 in cholangiocarcinoma: Potential therapeutic targets. Semin Liver Dis 2002;22:303-313, 2002.
66. Okaro AC, Deery AR, Hutchins RR, Davidson BR: The expression of anti- apoptotic proteins Bcl-2, Bcl-X, Mcl-1 in benign, dysplastic, and malignant biliary epithelium. J Clin Pathol 2001;54:927-932.
67. Nzeako UC, Guicciardi ME, Yoon JH, Bronk SF, Gores GJ: COX-2 inhibits Fas-mediated apoptosis in cholangiocarcinoma cells. Hepatology 2002;35:552-559.
68. Ahn E-Y, Pan G, Vickers SM, McDonald JM: IFN-γ upregulates apoptosis-related molecules and enhances FAS-mediated apoptosis in human cholangiocarcinoma. Int J Cancer 2002;100:445-451.
69. Vickers SM, Jhala NC, Ahn E-Y, McDonald JM, Pan G, Bland KI: Tamoxifen (TMX)/Fas induced growth inhibition of human cholangiocarcinoma (HCC) by gamma interferon (IFN-γ). Ann Surg 2002;235:872-878.
70. Lai G-H, Zhang Z, Sirica AE: Celecoxib acts in a cyclooxygenase-2- independent manner and in synergy with Emodin to suppress rat cholangiocarcinoma growth in vitro through a mechanism involving enhanced Akt inactivation and increased activation of caspases-9 and -3. Mol Cancer Therapeut 2003;2:265-271.
71. Satarun S, Haswell-Elkins MR, Tsuda M, Mairiang P, Sithithaworn P, Mairiang E, Esumi H, Sukprasert S, Yongvanit P, Elkins DB: Thiocyanate- independent nitrosation in humans with carcinogenic parasite infection. Carcinogenesis 1996;17:1075-1081.
72. Jaiswal M, LaRusso NF, Burgart LJ, Gores GJ: Inflammatory cytokines induce DNA damage and inhibit DNA repair in cholangiocarcinoma cells by a nitric oxide-dependent mechanism. Cancer Res 2000;60:184-190.
73. Sons HU, Borchard F: Carcinoma of the extrahepatic bile ducts: A post-mortem study of 65 cases and review of the literature. J Surg Oncol 1987;34:6-12.
74. Pitt HA, Dooley WC, Yeo CJ, Cameron JL: Malignancies of the biliary tree. Curr Probl Surg 1995;32:1-90.
75. Washburn WK, Lewis WD, Jenkins RL: Aggressive surgical resection for cholangiocarcinoma. Arch Surg 1995;130:270-276.
76. Ramage JK, Donaghy A, Farrant JM, Iorns R, Williams R. Serum tumor markers for the diagnosis of cholangiocarcinoma in primary sclerosing cholangitis. Gastroentrology 1995;108:865-869.
77. Chalasani N, Baluyut A, Ismail A, Zaman A, Sood G, Ghalib R, McCashland TM, Reddy KR, Zervos X, Anbari MA, Hoen H: Cholangiocarcinoma in patients with primary sclerosing cholangitis: A multicenter case-control study. Hepatology 2000;31:247-248.
78. Patel AH, Harnois DM, Klee GG, LaRusso NF, Gores GF: The utility of CA 19-9 in the diagnoses of cholangiocarcinoma in patients without primary sclerosing cholangitis. Am J Gastroenterol 2000;95:204-207.
79. Chen CY, Shiesh SC, Tsao HC, Lin XZ: The assessment of biliary CA 125, CA 19-9, and CEA in diagnosing cholangiocarcinoma - The influence of sampling time and hepatolithiasis. Hepatogastroenterology 2002;49:616-620.
80. Khan SA, Davidson BR, Goldin R, Pereira SP, Rosenberg WMC, Taylor-Robinson SD, Thillainayagam AV, Thomas HC, Thursz MR, Wasan H: Guidelines for the diagnosis and treatment of cholangiocarcinoma: Consensus document. Gut 2002;51(suppl VI): vi1-vi9.
81. Yamashita Y, Takahashi M, Kanazawa S, Charnsangavej C, Wallace S: Parenchymal changes of the liver in cholangiocarcinoma: CT evaluation. Gastrointest Radiol 1992;17:161-166.
82. Teefey SA, Hildeboldt CC, Dehdashti F, Siegel BA, Peters MG, Heiken JP, Brown JJ, McFarland EG, Middleton WD, Balfe DM, Ritter JH: Detection of primary hepatic malignancy in liver transplant candidates: Prospective comparison of CT, MR imaging, US, and PET. Radiology 2003;226:533-542.
83. Wiersema MJ, Vilmann P, Giovannini M, Chang KJ, Wiersema LM: Endosonographyguided fine-needle aspiration biopsy: Diagnostic accuracy and complication assessment. Gastroenterology 1997;112:1087-1095.
84. Magnuson TH, Bender JS, Duncan MD, Ahrendt SA, Harmon JW, Regan F: Utility of magnetic resonance cholangiography in the evaluation of biliary obstruction. J Am Coll Surg 1999;1:63-71.
85. Lee SS, Kim MH, Lee SK, Kim TK, Seo DW, Park JS, Hwang CY, Chang HS, Min YI: MR cholangiography versus cholangioscopy for evaluation of longitudinal extension of hilar cholangiocarcinoma. Gastrointest Endosc 2002;56:25-32.
86. Farrell RJ, Agarwal B, Brandwein SL, Underhill J, Chuttani R, Pleskow DK: Intraductal US is a useful adjunct to ERCP for distinguishing malignant from benign biliary strictures. Gastrointest Endosc 2002;56:681-687.
87. Albores-Saavedra J, Henson DE, Sorbin LH: Histological typing of tumours of the gallbladder and extrahepatic bile ducts, ed 2. Berlin, Springer, 1991.
88. Klatskin G: Adenocarcinoma of the hepatic duct at its bifurcation within the porta hepatis. An unusual tumor with distinctive clinical and pathological features. Am J Med 1965;38:241-256.
89. Nakeeb A, Pitt HA, Sohn TA, Coleman J, Abrams RA, Piantadosi S, Hruban RH, Lillemoe KD, Yeo CJ, Cameron JL: Cholangiocarcinoma. A spectrum of intrahepatic, perihilar, and distal tumors. Ann Surg 1996;224:463-475.
90. Bismuth H, Corlette MB: Intrahepatic cholangioenteric anastomosis in carcinoma of the hilus of the liver. Surg Gynecol Obstet 1975;140:170-176.
91. AJCC (American Joint Committee on Cancer): Cancer Staging Manual, ed 6, Greene FL, Page DL, Fleming ID (eds). New York, Springer,2002.
92. Pichlmayr R, Lamesch P, Weimann A, Tusch G, Ringe B: Surgical treatment of cholangiocellular carcinoma. World J Surg 1995;19:83-88.
93. Kluge R, Schmidt F, Cac K, Barthel H, Hesse S, Georgi P, Seese A, Huster D, Berr F: Positron emission tomography with [(18)F]fluoro-2-deoxy-D-glucose for diagnosis and staging of bile duct cancer. Hepatology 2001;33:1029-1035.
94. Tamada K, Ido K, Ueno N, Ichiyama M, Nishizono T, Wada S, Noda T, Tano S, Aizawa T, et al: Assessment of the course and variations of the hepatic artery in bile duct cancer by intraductal ultrasonography. Gastrointest Endosc 1996;44:249-256.
95. Tamada K, Ido K, Ueno N, Ichiyama M, Nishizono T, Wada S, Noda T, Tano S, Aizawa T, et al: Assessment of portal vein invasion by bile duct cancer using intraductal ultrasonography. Endoscopy 1995;27:573-578.
96. Tamada K, Ueno N, Ichiyama M, Tomiyama T, Nishizono T, Wada S, Oohashi A, Tano S, Ido K, Kimura K: Assessment of pancreatic parenchymal invasion by bile duct cancer using intraductal ultrasonography. Endoscopy 1996;28:492-496.
97. Weber SM, DeMatteo RP, Fong Y, Blumgart LH, Jarnagin WR: Staging laparoscopy in patients with extrahepatic biliary carcinoma. Analysis of 100 patients. Ann Surg 2002;235:392-399.
98. Martin RC 2nd, Fong Y, DeMatteo RP, Brown K, Blumgart LH, Jarnagin WR: Peritoneal washings are not predictive of occult peritoneal disease in patients with hilar cholangiocarcinoma. J Am Coll Surg 2001;193:620-625.
99. Longmire WP, McArthur MS, Bastoumis EA, Hiatt J: Carcinoma of the extrahepatic biliary tract. Ann Surg 1973;173:333-343.
100. Jarnagin WR: Cholangiocarcinoma of the extrahepatic bile ducts. Semin Surg Oncol 2000;19:156-176.
101. Kosuge T, Yamamoto J, Shimada K, Yamasaki S, Makuuchi M: Improved surgical results for hilar cholangiocarcinoma with procedures including major hepatic resection. Ann Surg 1999;5:663-671.
102. Klempnauer J, Ridder JG, Werner M, Weimann A, Pichlmayr R: What constitutes long term survival after surgery for hilar cholangiocarcinoma? Cancer 1997;79:26-34.
103. Nimura Y: Extended surgery in bilio-pancreatic cancer: The Japanese experience. Semin Oncol 2002;29:17-22.
104. Nakeeb A, Tran KQ, Black MJ, Erickson BA, Ritch PS, Quebbeman EJ, Wilson SD, Demeure MJ, Rilling WS, Dua KS, Pitt HA: Improved survival in resected biliary malignancies. Surgery 2002;132:555-563.
105. Burke EC, Jarnagin WR, Hochwald SN, Pisters PW, Fong Y, Blumgart LH. Hilar cholangiocarcinoma: Patterns of spread, the importance of hepatic resection for curative operation, and a presurgical clinical staging system. Ann Surg 1998;228:385-394.
106. Meyer CG, Penn I, James L: Liver transplantation for cholangiocarcinoma: Results in 207 patients. Transplantation 2000;69:1633-1637.
107. Hejna M, Pruckmayer M, Raderer M: The role of chemotherapy and radiation in the management of biliary cancer: A review of the literature. Eur J Cancer 1998;34:977-986.
108. Todoroki T: Chemotherapy for bile duct carcinoma in the light of adjuvant chemotherapy to surgery. Hepatogastroenterology 2000;47:644-649.
109. Falkson G, MacIntyre JM, Moertel CG: Eastern Cooperative Oncology Group experience with chemotherapy for inoperable gallbladder and bile duct cancer. Cancer 1984;54:965-969.
110. Kubicka S, Rudolf KL, Tietze MK, Lorenz M, Manns M: Phase II study of systemic gemcitabine chemotherapy for advanced unresectable hepatobiliary carcinomas. Hepatogastroenterology 2001;48:783-789.
111. Colleoni M, Di Bartolomeo M, Di Leo A, Zilembo N, Carnaghi C, Pandolfi A, Rimassa L, Artale S, Bajetta E: Oral chemotherapy with doxifluridine and folinic acid in biliary tract cancer. Eur J Oncol 1995;31A:2427-2428.
112. Harvey JH, Smith FP, Schein PS: 5-fluorouracil, mitomycin, and doxorubicin (FAM) in carcinoma of the biliary tract. J Clin Oncol 1984;2:1245-1248.
113. Sanz-Altamira PM, Ferrante K, Jenkins RL, Lewis WD, Huberman MS, Stuart KE: A phase II trial of 5-fluorouracil, leucovorin, and carboplatin in patients with unresectable biliary tree carcinoma. Cancer 1998;82:2321-2325.
114. Patt YZ, Jones DV Jr, Hoque A, Lozano R, Markowitz A, Raijman I, Lynch P, Charnsangavej C: Phase II trial of intravenous fluorouracil and subcutaneous interferon alfa-2b for biliary tract cancer. J Clin Oncol 1996;14:2311-2315.
115. Raderer M, Hejna MH, Valencak JB, Kornek GV, Weinlander GS, Bareck E, Lenauer J, Brodowicz T, Lang F, Scheithauer W: Two consecutive phase II studies of 5-fluorouracil/leucovorin/mitomycin C and of gemcitabine in patients with advanced biliary cancer. Oncology 1999;56:177-180.
116. Choi CW, Choi IK, Seo JH, Kim BS, Kim JS, Kim CD, Um SH, Kim JS, Kim YH: Effects of 5-fluorouracil and leucovorin in the treatment of pancreatic-biliary tract adenocarcinomas. Am J Clin Oncol 2000;23:425-428.
117. Takada T, Amano H, Yasuda H, Nimura Y, Matsushiro T, Kato H, Nagakawa T, Nakayama T: Is postoperative adjuvant chemotherapy useful in gallbladder carcinoma? Cancer 2002;95:1685-1695.
118. Cantore M, Rabbi C, Guadagni S, Zamagni D, Aitini E: Intra-arterial hepatic chemotherapy combined with continuous infusion of 5-fluorouracil in patients with metastatic cholangiocarcinoma. Ann Oncol 2002;12:1687-1688.
119. Pitt HA, Nakeeb A, Abrams RA, Coleman J, Piantadosi S, Yeo CJ, Lillemoe KD, Cameron JL: Perihilar cholangiocarcinoma. Postoperative radiotherapy does not improve survival. Ann Surg 1995;221:788-797.
120. McMasters KM, Tuttle TM, Leach SD, Rich T, Cleary KR, Evans DB, Curley SA: Neoadjuvant chemoradiation for extrahepatic cholangiocarcinoma. Am J Surg 1997;174:605-609.
121. De Vreede I, Steers JL, Burch PA, Rosen CB, Gunderson LL, Haddock MG, Burgart L, Gores GJ: Prolonged disease-free survival after orthotopic liver transplantation plus adjuvant chemoirradiation for cholangiocarcinoma. Liver Transpl 2000;6:309-316.
122. Sudan D, DeRoover A, Chinnakotla S, Fox I, Shaw B Jr, McCashland T, Sorrell M, Tempero M, Langnas A: Radiochemotherapy and transplantation allow long-term survival for nonresectable hilar cholangiocarcinoma. Am J Translplant 2002;2:774-779.
123. Nordback IH, Pitt HA, Coleman J, Venbrux AC, Dooley WC, Yeu NN, Cameron JL: Unresectable hilar cholangiocarcinoma: Percutaneous versus operative palliation. Surgery 1994;115:597-603.
124. Ortner M: Photodynamic therapy for cholangiocarcinoma. J Hepato-Biliary-Pancreatic Surg 2001;8:137-139.
125. Ortner M, Liebetruth J, Schreiber S, Hanft M, Wruck U, Fusco V, Müller J, Hortnagl H, Lochs H: Photodynamic therapy of nonresectable cholangiocarcinoma. Gastroenterology 1998;114:536-542.
126. Zoepf T, Jakobs R, Rosenbaum A, Apel D, Arnold JC, Riemann JF: Photodynamic therapy with 5-aminolevulinic acid is not effective in bile duct cancer. Gastrointest Endosc 2001;54:763-766.
127. Rumalla A, Baron TH: Evaluation and endoscopic palliation of cholangiocarcinoma. Dig Dis 1999;17:194-200.
128. De Palma GD, Galloro G, Siciliano S, Iovino P, Catanzano C: Unilateral versus bilateral endoscopic hepatic duct drainage in patients with malignant hilar biliary obstruction: Results of a prospective, randomized, and controlled study. Gastrointest Endosc 2001;53:547-553.